Addex Therapeutics: 2023 Financial Results and Corporate Update


Here is the SEO-optimized article for the biotech publication, based on the provided context and limited to 200 words:

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, has announced its financial results for the full year ended December 31, 2023. The company reported a solid financial performance and provided an update on its corporate activities.

During the year, Addex Therapeutics made significant progress in advancing its pipeline of innovative allosteric modulators targeting various central nervous system disorders. The company’s lead product candidate, dipraglurant, continued to show promising results in clinical trials for the treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID).

In addition to its clinical achievements, Addex Therapeutics strengthened its financial position through successful fundraising efforts and strategic partnerships. The company remains well-capitalized to support its ongoing research and development activities, as well as to explore new opportunities for growth.

Looking ahead, Addex Therapeutics is committed to advancing its pipeline and delivering innovative therapies to patients in need. The company’s management team expressed confidence in its ability to achieve key milestones and create value for shareholders in the coming year.